Roche Acquires Good Therapeutics to Gain PD-1-regulated IL-2 Program

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.

Amgen Inc. Acquires Rodeo Therapeutics

March 30, 2021

Biotechnology

Amgen Inc. has agreed to acquire privately held Rodeo Therapeutics, a Seattle-based biopharmaceutical company focused on small-molecule modulators of prostaglandin biology, including a lead 15-PGDH program. The deal includes a $55 million upfront cash payment plus up to $666 million in potential contingent milestone payments and is intended to expand Amgen's inflammation and tissue-regeneration capabilities.

Sun Pharma Acquires Checkpoint Therapeutics

May 30, 2025

Biotechnology

Sun Pharmaceutical Industries Limited has completed the acquisition of Checkpoint Therapeutics, Inc., acquiring all outstanding shares for $4.10 per share in cash plus a contingent value right. The deal gives Sun Pharma ownership of UNLOXCYT (cosibelimab-ipdl), the FDA-approved anti-PD-L1 therapy for advanced cutaneous squamous cell carcinoma, and expands its oncology/onco-derm product portfolio.

Tome Biosciences Acquires Replace Therapeutics

January 5, 2024

Biotechnology

Tome Biosciences has acquired Replace Therapeutics in a merger valued at $65 million in up-front and near-term milestones and up to $185 million total through a mix of cash and stock. Replace will become a wholly owned subsidiary of Tome, adding its ligase-mediated programmable genomic integration (L-PGI) technology to complement Tome's large-DNA integrase-mediated PGI platform to expand the company's gene‑editing capabilities.

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.

Pharmacosmos Acquires G1 Therapeutics

August 7, 2024

Biotechnology

Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.